In Noncirrhotic Non-Alcoholic Steatohepatitis Noncirrhotic non-alcoholic steatohepatitis (NASH) is liver inflammation and damage caused by excess fat in the liver. Because of the damage, the liver doesn't work as well as it should. Lipaglyn Tablet reduces fat deposition thereby improving its overall functioning. In Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease is a condition in which there is an increased buildup of fat in the liver. It affects people who drink little to no alcohol. Lipaglyn Tablet protects the liver and reduces the risk of liver failure. In Diabetic dyslipidemia (high cholesterol in diabetes) Lipaglyn Tablet helps in the management of high cholesterol, as well as blood sugar levels in people with type 2 diabetes. It is mainly used in people whose cholesterol levels are not controlled by statin therapy alone. By controlling high cholesterol levels, Lipaglyn Tablet helps reduce the risk of heart diseases.
It is unsafe to consume alcohol with Lipaglyn Tablet.
Lipaglyn Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Lipaglyn Tablet should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Lipaglyn Tablet does not usually affect your ability to drive.
There is limited information available on the use of Lipaglyn Tablet in patients with kidney disease. Please consult your doctor.
There is limited information available on the use of Lipaglyn Tablet in patients with liver disease. Please consult your doctor.
If you miss a dose, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and take it at the next scheduled time. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Zydus Cadila || ₹14.5/tablet (25% cheaper)